These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 26852935)
1. Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors. Kemp M Prog Med Chem; 2016; 55():149-92. PubMed ID: 26852935 [TBL] [Abstract][Full Text] [Related]
2. Inhibiting the deubiquitinating enzymes (DUBs). Ndubaku C; Tsui V J Med Chem; 2015 Feb; 58(4):1581-95. PubMed ID: 25364867 [TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating enzyme inhibitors and their potential in cancer therapy. Crosas B Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039 [TBL] [Abstract][Full Text] [Related]
4. Deubiquitylating enzymes and drug discovery: emerging opportunities. Harrigan JA; Jacq X; Martin NM; Jackson SP Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms for regulating deubiquitinating enzymes. Wolberger C Protein Sci; 2014 Apr; 23(4):344-53. PubMed ID: 24403057 [TBL] [Abstract][Full Text] [Related]
11. Deubiquitinase inhibition as a cancer therapeutic strategy. D'Arcy P; Wang X; Linder S Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757 [TBL] [Abstract][Full Text] [Related]
12. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition. Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579 [TBL] [Abstract][Full Text] [Related]
13. Activity-based diubiquitin probes for elucidating the linkage specificity of deubiquitinating enzymes. Li G; Liang Q; Gong P; Tencer AH; Zhuang Z Chem Commun (Camb); 2014 Jan; 50(2):216-8. PubMed ID: 24225431 [TBL] [Abstract][Full Text] [Related]
14. Regulation of proteolysis by human deubiquitinating enzymes. Eletr ZM; Wilkinson KD Biochim Biophys Acta; 2014 Jan; 1843(1):114-28. PubMed ID: 23845989 [TBL] [Abstract][Full Text] [Related]
15. Targeting the ubiquitin pathway for cancer treatment. Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145 [TBL] [Abstract][Full Text] [Related]
18. A Selective Inhibitor of Ubiquitin-Specific Protease 4 Suppresses Colorectal Cancer Progression by Regulating β-Catenin Signaling. Nguyen HH; Kim T; Nguyen T; Hahn MJ; Yun SI; Kim KK Cell Physiol Biochem; 2019; 53(1):157-171. PubMed ID: 31251006 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors? Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292 [TBL] [Abstract][Full Text] [Related]
20. The deubiquitinating enzyme activity of USP22 is necessary for regulating HeLa cell growth. Liu YL; Zheng J; Tang LJ; Han W; Wang JM; Liu DW; Tian QB Gene; 2015 Nov; 572(1):49-56. PubMed ID: 26143114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]